tradingkey.logo
tradingkey.logo
Search

Enliven Therapeutics Inc

ELVN
Add to Watchlist
58.810USD
+0.750+1.29%
Close 08-14 16:00ETQuotes delayed by 15 min
4.31BMarket Cap
LossP/E TTM

ELVN Income Statement

You can find the annual or quarterly income statement of Enliven Therapeutics Inc here for insights into the performance and operational efficiency of Enliven Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q2
FY2019Q1
Operating expenses
30.17%37.21M
-12.21%27.82M
27.47%34.28M
-7.29%25.10M
16.18%28.58M
21.96%31.69M
18.33%26.90M
11.63%27.07M
22.20%24.60M
58.28%25.99M
597.85%22.73M
401.93%24.25M
74.76%20.13M
11.98%16.42M
-77.28%3.26M
-64.63%4.83M
-12.51%11.52M
42.62%14.66M
24.10%14.33M
9.32%13.66M
27.83%13.17M
39.83%10.28M
--11.55M
--12.49M
85.39%10.30M
75.30%7.35M
--5.56M
--4.19M
R&D expenses
34.92%29.00M
-16.90%20.69M
2.51%21.25M
-14.27%18.23M
14.16%21.49M
24.66%24.89M
15.74%20.72M
8.43%21.26M
23.99%18.83M
68.10%19.97M
9847.22%17.91M
10672.53%19.61M
104.93%15.18M
6.37%11.88M
-98.34%180.00K
-98.25%182.00K
-26.45%7.41M
56.98%11.17M
21.17%10.86M
9.06%10.40M
28.02%10.07M
22.82%7.12M
--8.96M
--9.53M
80.23%7.87M
62.72%5.79M
--4.37M
--3.56M
Depreciation, depletion, and amortization
-91.36%7.00K
-81.08%14.00K
275.00%300.00K
-22.50%62.00K
2.53%81.00K
-6.33%74.00K
0.00%80.00K
1.27%80.00K
6.76%79.00K
17.91%79.00K
--80.00K
-24.04%79.00K
-84.68%74.00K
168.00%67.00K
----
333.33%104.00K
1832.00%483.00K
0.00%25.00K
8.70%25.00K
-4.00%24.00K
0.00%25.00K
4.17%25.00K
--23.00K
--25.00K
--25.00K
--24.00K
----
--0.00
Operating profit
-30.17%-37.21M
12.21%-27.82M
-27.47%-34.28M
7.29%-25.10M
-16.18%-28.58M
-21.96%-31.69M
-18.33%-26.90M
-11.63%-27.07M
-22.20%-24.60M
-58.28%-25.99M
-597.85%-22.73M
-401.93%-24.25M
-74.76%-20.13M
-11.98%-16.42M
77.28%-3.26M
64.63%-4.83M
12.51%-11.52M
-42.62%-14.66M
-24.10%-14.33M
-9.32%-13.66M
-27.83%-13.17M
-39.83%-10.28M
---11.55M
---12.49M
-85.39%-10.30M
-75.30%-7.35M
---5.56M
---4.19M
Net non-operating interest income (expenses)
Non-operating interest income
45.56%4.73M
31.29%4.20M
24.27%4.62M
28.89%4.95M
-20.44%3.25M
-1.66%3.20M
10.33%3.72M
9.94%3.84M
19.72%4.09M
91.85%3.25M
556.53%3.37M
1342.98%3.49M
3002.73%3.41M
2071.79%1.69M
612.50%513.00K
706.67%242.00K
129.17%110.00K
-6.02%78.00K
-37.39%72.00K
-76.19%30.00K
-56.36%48.00K
-37.12%83.00K
--115.00K
--126.00K
-31.25%110.00K
--132.00K
--160.00K
--0.00
Special income (expenses)
----
----
--0.00
-100.00%0.00
-100.00%0.00
----
--0.00
--73.00K
--800.00K
----
----
----
----
----
--0.00
---200.00K
----
----
----
----
----
----
----
----
----
----
----
----
- Gains from disposal of fixed assets
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--35.00M
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
-300.00%-8.00K
100.00%0.00
--0.00
--0.00
-100.00%-2.00K
-4600.00%-47.00K
100.00%0.00
100.00%0.00
---1.00K
---1.00K
-152.94%-9.00K
-107.22%-13.00K
----
----
129.82%17.00K
1100.00%180.00K
5.00%-38.00K
6.67%-56.00K
31.33%-57.00K
67.27%-18.00K
-233.33%-40.00K
-1300.00%-60.00K
---83.00K
---55.00K
---12.00K
--5.00K
--0.00
--0.00
Income before tax
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-28.49%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-17.92%-19.72M
-54.43%-22.74M
-160.02%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
325.39%32.27M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
-28.98%-13.16M
-42.16%-10.26M
---11.52M
---12.42M
-89.07%-10.20M
-72.03%-7.21M
---5.40M
---4.19M
Income tax
----
----
--0.00
--0.00
-100.00%0.00
----
--0.00
--0.00
--232.00K
----
----
----
----
----
--88.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
-28.98%-13.16M
-42.16%-10.26M
---11.52M
---12.42M
-89.07%-10.20M
-72.03%-7.21M
---5.40M
---4.19M
Net income from continuous operations
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
-28.98%-13.16M
-42.16%-10.26M
---11.52M
---12.42M
-89.07%-10.20M
-72.03%-7.21M
---5.40M
---4.19M
Net income attributable to controlling interests
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
-28.98%-13.16M
31.95%-10.26M
---11.52M
---12.42M
-89.07%-10.20M
-259.39%-15.07M
---5.40M
---4.19M
Preferred share dividend
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
----
----
--0.00
--7.86M
----
--0.00
Net income attributable to common shareholders
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
-28.98%-13.16M
31.95%-10.26M
---11.52M
---12.42M
-89.07%-10.20M
-259.39%-15.07M
---5.40M
---4.19M
Basic earnings per share
-0.96%-0.49
34.03%-0.38
-2.51%-0.48
32.36%-0.32
-17.17%-0.49
-5.46%-0.57
1.18%-0.46
5.22%-0.48
-1.66%-0.41
32.00%-0.54
-109.60%-0.47
27.82%-0.51
76.57%-0.41
64.30%-0.80
325.27%4.90
68.01%-0.70
41.38%-1.74
4.57%-2.23
16.90%-2.17
23.45%-2.19
-25.19%-2.97
86.48%-2.33
---2.62
---2.86
-82.26%-2.37
-1605.30%-17.26
---1.30
---1.01
Diluted earnings per share
-0.96%-0.49
34.03%-0.38
-2.51%-0.48
32.36%-0.32
-17.17%-0.49
-5.46%-0.57
1.18%-0.46
5.22%-0.48
-1.66%-0.41
32.00%-0.54
-109.75%-0.47
27.82%-0.51
76.57%-0.41
64.30%-0.80
321.95%4.83
68.01%-0.70
41.38%-1.74
4.57%-2.23
16.90%-2.17
23.45%-2.19
-25.19%-2.97
86.48%-2.33
---2.62
---2.86
-82.26%-2.37
-1605.30%-17.26
---1.30
---1.01
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Enliven Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing ELVN stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Enliven Therapeutics Inc's net income for the year?

Enliven Therapeutics Inc posted -103.69M in net income for fiscal year 2025.

How much net income did Enliven Therapeutics Inc post in the last quarter?

Enliven Therapeutics Inc reported -32.48M in net income for the latest quarter。

What was Enliven Therapeutics Inc's annual operating profit?

Enliven Therapeutics Inc's operating income was -119.66M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.